1. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999. 44:1–13.
2. Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut. 1975. 16:249–254.
3. Quezada S, Turner PL, Alexiev B, Daly B, Cross R. Severe refractory orofacial Crohn's disease: report of a case. Dig Dis Sci. 2009. 54:2290–2295.
4. Sanderson J, Nunes C, Escudier M, et al. Oro-facial granulomatosis: Crohn's disease or a new inflammatory bowel disease? Inflamm Bowel Dis. 2005. 11:840–846.
5. Rowland M, Fleming P, Bourke B. Looking in the mouth for Crohn's disease. Inflamm Bowel Dis. 2010. 16:332–337.
6. Scully C, Cochran KM, Russell RI, et al. Crohn's disease of the mouth: an indicator of intestinal involvement. Gut. 1982. 23:198–201.
7. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis. 2001. 7:38–42.
8. Graham DB, Jager DL, Borum ML. Metastatic Crohn's disease of the face. Dig Dis Sci. 2006. 51:2062–2063.
9. Wiesenfeld D, Ferguson MM, Mitchell DN, et al. Oro-facial granulomatosis--a clinical and pathological analysis. Q J Med. 1985. 54:101–113.
10. Tilakaratne WM, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. J Oral Pathol Med. 2008. 37:191–195.
11. Ottaviani F, Schindler A, Capaccio P, Petrone M, Bianchi Porro G. New therapy for orolaryngeal manifestations of Crohn's disease. Ann Otol Rhinol Laryngol. 2003. 112:37–39.
12. Brunner B, Hirschi C, Weimann R, Seibold F. Treatment-resistant lingual Crohn's disease disappears after infliximab. Scand J Gastroenterol. 2005. 40:1255–1259.
13. Cardoso H, Nunes AC, Carneiro F, Tavarela Veloso F. Successful infliximab therapy for oral Crohn's disease. Inflamm Bowel Dis. 2006. 12:337–338.
14. Staines KS, Green R, Felix DH. The management of fistulizing oral Crohn's disease with infliximab. J Oral Pathol Med. 2007. 36:444–446.
15. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999. 117:1278–1287.
16. Sciubba JJ, Said-Al-Naief N. Orofacial granulomatosis: presentation, pathology and management of 13 cases. J Oral Pathol Med. 2003. 32:576–585.
17. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003. 95:576–585.